Health Care Technology

Simulations Plus

Simulations Plus and Nvidia Collaborate on Expanding GPU-Accelerated AI-Assisted Modeling Workflow

Simulations Plus released FY2026 Semi-Annual earnings on April 10 After-Market EST, actual revenue USD 42.71 M, actual EPS USD 0.2586

Simulations Plus released FY2026 Q2 earnings on April 9 After-Market EST, actual revenue USD 24.29 M (forecast USD 21.66 M), actual EPS USD 0.22 (forecast USD 0.1975)

Simulations Plus reports 8% Q2 revenue growth, beating expectations

Simulations Plus to Release FY2026 Q2 Earnings on April 9 After-Market EST, Forecast Revenue USD 21.66 M, EPS USD 0.1975

Simulations Plus Announces Strategic Partnership Plan for AI-driven Modeling

Simulations Plus released FY2026 Q1 earnings on January 8 After-Market (EST), actual revenue USD 18.42M (forecast USD 18.06M), actual EPS USD 0.03 (forecast USD 0.08)

Simulations Plus to Release FY2026 Q1 Earnings on January 8 After-Market EST, Forecast Revenue USD 18.06 M, EPS USD 0.085

Simulations Plus Inc. to Hold Virtual Investor Day

Simulations Plus Optimizes Drug Development with FDA Guidelines

Simulations Plus released FY2025 Annual Earnings on December 1 After-Market (EST), actual revenue USD 79.18 M (forecast USD 79.11 M), actual EPS USD -3.22 (forecast USD -3.185)

Simulations Plus released FY2025 Q4 earnings on December 1 After-Market EST, actual revenue USD 17.46 M (forecast USD 17.39 M), actual EPS USD -0.0338 (forecast USD -0.02)

Simulations Plus to Release FY2025 Q4 Earnings on December 1 After-Market (EST), Forecast Revenue USD 17.39M, EPS USD -0.02

Analyst Schoenhaus Covers Healthcare Sector

Simulations Plus Reports 2025 Preliminary Earnings and Guides 2026 Revenue

Simulations Plus Reports Massive Loss and Stock Price Plummets

Investigation into Simulations Plus Shareholder Losses

Simulations Plus and Polish Academy Collaboration Achieves AI Drug Design Breakthrough

JPMorgan Predicts S&P 500 to Reach 6000 by Year-End

Simulations Plus Inc. Replaces Auditor

Co-Diagnostics

Netcapital

NewGenIvf

Liminatus Pharma

Agape ATP

Tradr 2X Long QBTS Daily ETF

Tradr 2X Long RGTI Daily ETF

Defiance Daily Target 2X Long RGTI ETF

Wheeler Real Estate

Sunshine Biopharma

Simulations Plus, Inc (SLP.US) Fiscal Year 2026 Second Quarter Earnings Conference Call

Simulations Plus, Inc (SLP.US) Q1 Fiscal Year 2026 Earnings Conference Call

Simulations Plus, Inc (SLP.US) Q4 Fiscal Year 2025 Earnings Conference Call

Simulations Plus, Inc (SLP.US) Q3 Fiscal Year 2025 Earnings Conference Call

Simulations Plus, Inc (SLP.US) Q2 Fiscal Year 2025 Earnings Conference Call

Simulations Plus, Inc (SLP.US) Q1 Fiscal Year 2025 Earnings Conference Call

SimScale has launched its Engineering AI agents for enterprise teams, enabling organizations to automate the entire simulation workflow. This transition from strategic customer deployments to public availability aims to alleviate time constraints faced by engineering teams. The AI agents can autonomously handle tasks from CAD preparation to validation reporting, significantly reducing project timelines. Customers report that tasks that previously took months can now be completed in hours. SimScale has opened a guided pilot waitlist for organizations interested in adopting this technology.

fidelity

iShares Expanded Tech Software Sector ETF

SPDR S&P Software

From Engineering Intent to Validated Design in Minutes: SimScale Opens Engineering AI Agents to All Enterprise Teams

AVTX

APUS

TMDX

PAVM

AKAN

MNKD

GCTK

In Wednesday's pre-market session, Avalo Therapeutics (AVTX) saw a significant gain of 50.9%, reaching $24.53, while GlucoTrack (GCTK) rose by 45.2% to $1.06. Other notable gainers included Simulations Plus (SLP) up 35.66% and MannKind (MNKD) up 20.27%. Conversely, PAVmed (PAVM) dropped 27.9% to $5.8, and Apimeds Pharmaceuticals (APUS) fell 27.67% to $2.17. TransMedics Group (TMDX) and Akanda (AKAN) also experienced declines of 22.04% and 19.22%, respectively. The fluctuations follow recent earnings reports for Q1 and Q4.

benzinga_article

Avalo Therapeutics

Apimeds Pharmaceuticals US

TransMedics

PAVmed

Akanda

Mannkind

GlucoTrack

Cypherpunk Tech

Atlantic

Hyperion DeFi

Alphatec

ATLANTIC INTERNATIONAL CORP C/WTS 31/08/2026 (TO PUR COM)

PAVMED INC C/WTS 30/04/2025(TO PUR COM) CLASS Z

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

NVDA

NVDY

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows | SLP Stock News

StockTitan

NVIDIA

YieldMax NVDA Option Income Strategy ETF

T-Rex 2X Long NVIDIA Daily Target ETF

VanEck Semiconductor ETF

Direxion Semicon Bull 3X

iShares Semiconductor ETF

Direxion Daily NVDA Bull 2X Shares

GraniteShares 2x Long NVDA Daily ETF

Spdr Select Tech

NVIDIA Corporation

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows | SLP Stock News

PPLT

Berenberg Bank has reiterated a "buy" rating for Sylvania Platinum (LON:SLP) with a price target of GBX 166, indicating a potential upside of 71.13% from its previous close of GBX 97. The company has a market cap of £251.65 million and a price-to-earnings ratio of 6.96. Additionally, Sylvania Platinum's Board has authorized a stock buyback program, and insider trading activity includes a purchase of 65,100 shares by Martin Preece and a sale of 349,250 shares by Johannes Jacobus Prinsloo.

Market Beat

Platinum Grp Met

Abrdn Platinum ETF Trust

Sylvania Platinum's (SLP) "Buy" Rating Reiterated at Berenberg Bank

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products | SLP Stock News

Lonza

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products | SLP Stock News

Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School | SLP Stock News

Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School | SLP Stock News

Simulations Plus, Inc. CRO John Anthony Dibella II sold 1,000 shares of the company's stock at an average price of $13.37, totaling $13,370. Following the sale, he owns 89,140 shares valued at approximately $1.19 million, reflecting a 1.11% decrease in his position. The transaction was executed under a Rule 10b5-1 trading plan and disclosed to the SEC. Simulations Plus stock recently traded at $14.12, with a market cap of $285.29 million and a P/E ratio of -4.51. Analysts have mixed ratings on the stock, with a consensus target price of $24.40.

John Anthony Dibella II Sells 1,000 Shares of Simulations Plus (NASDAQ:SLP) Stock

Simulations Plus (NASDAQ:SLP) reported Q2 fiscal 2026 revenue of $24.3 million, surpassing guidance, with growth in software and services. CEO Sean O’Connor noted adjusted EBITDA of $8.7 million and a 36% margin. The company experienced a 91% renewal rate among clients and a services backlog of $24 million. Despite a strong first half, O’Connor described the operating environment as fragile due to macro uncertainties. The firm is embedding AI into its products and has ongoing collaborations with major pharmaceutical companies to enhance drug development workflows.

Simulations Plus Q2 Earnings Call Highlights

Simulations Plus (NASDAQ: SLP) saw a slight increase in stock price by 0.4% following its fiscal second quarter results, which exceeded revenue and profitability expectations. The company reported $24.3 million in revenue, an 8% year-over-year increase, with software revenue rising 9%. However, it lowered its full-year net income forecast to $0.75-$0.85 per share from $1.03-$1.10 due to a higher effective tax rate. Despite this guidance cut, the overall performance remains strong, indicating potential for future growth.

Why Simulations Plus stock inched higher today

Shares of Simulations Plus, Inc. (SLP) rose approximately 14% in pre-market trading on the Nasdaq following a report of higher Q2 earnings, driven by overall topline growth. The company reported a net income of $4.54 million ($0.22 per share) for Q2, up from $3.07 million ($0.15 per share) a year earlier. However, it lowered its FY26 adjusted EPS forecast to $0.75-$0.85 due to an increased expected tax rate, while maintaining annual revenue expectations of $79-$82 million, reflecting 0-4% growth year-over-year.

rttnews

Simulations Plus Shares Climb On Higher Q2 Results; Cuts FY26 Earnings View

Simulations Plus(SLP.US)

From Engineering Intent to Validated Design in Minutes: SimScale Opens Engineering AI Agents to All Enterprise Teams

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows | SLP Stock News

Sylvania Platinum's (SLP) "Buy" Rating Reiterated at Berenberg Bank

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products | SLP Stock News

Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School | SLP Stock News

John Anthony Dibella II Sells 1,000 Shares of Simulations Plus (NASDAQ:SLP) Stock

Simulations Plus Q2 Earnings Call Highlights

Why Simulations Plus stock inched higher today

Simulations Plus Shares Climb On Higher Q2 Results; Cuts FY26 Earnings View